{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:41:45Z","timestamp":1756384905390},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2010,11,26]],"date-time":"2010-11-26T00:00:00Z","timestamp":1290729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/2.0"},{"start":{"date-parts":[[2010,11,26]],"date-time":"2010-11-26T00:00:00Z","timestamp":1290729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/2.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1007\/s00228-010-0950-y","type":"journal-article","created":{"date-parts":[[2010,11,25]],"date-time":"2010-11-25T12:03:44Z","timestamp":1290686624000},"page":"371-381","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters"],"prefix":"10.1007","volume":"67","author":[{"given":"Christof","family":"Geisen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beate","family":"Luxembourg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Watzka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan W.","family":"Toennes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja","family":"Sittinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milka","family":"Marinova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"von Ahsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edelgard","family":"Lindhoff-Last","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erhard","family":"Seifried","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Oldenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,11,26]]},"reference":[{"key":"950_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/bmj.329.7456.15","volume":"329","author":"M Pirmohamed","year":"2004","unstructured":"Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 329:15\u201319","journal-title":"BMJ"},{"key":"950_CR2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1472-6904-7-8","volume":"7","author":"KJ Patel","year":"2007","unstructured":"Patel KJ, Kedia MS, Bajpai D, Mehta SS, Kshirsagar NA, Gogtay NJ (2007) Evaluation of the prevalence and economic burden of adverse drug reactions presenting to the medical emergency department of a tertiary referral centre: a prospective study. BMC Clin Pharmacol 7:8","journal-title":"BMC Clin Pharmacol"},{"key":"950_CR3","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/S0140-6736(96)01109-9","volume":"348","author":"G Palareti","year":"1996","unstructured":"Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D\u2019Angelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto G, Berrettini M, Musolesi S (1996) Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian study on complications of oral anticoagulant therapy. Lancet 348:423\u2013428","journal-title":"Lancet"},{"key":"950_CR4","doi-asserted-by":"publisher","first-page":"160S","DOI":"10.1378\/chest.08-0670","volume":"133","author":"J Ansell","year":"2008","unstructured":"Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G, American College of Chest Physicians (2008) Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133:160S\u2013198S","journal-title":"Chest"},{"key":"950_CR5","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1089\/ars.2006.8.347","volume":"8","author":"J Oldenburg","year":"2006","unstructured":"Oldenburg J, Bevans CG, M\u00fcller CR, Watzka M (2006) Vitamin K epoxide reductase complex subunit 1 (VKORC1): the key protein of the vitamin K cycle. Antioxid Redox Signal 8:347\u2013353","journal-title":"Antioxid Redox Signal"},{"key":"950_CR6","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1160\/TH07-07-0454","volume":"98","author":"J Oldenburg","year":"2007","unstructured":"Oldenburg J, Bevans CG, Fregin A, Geisen C, M\u00fcller-Reible C, Watzka M (2007) Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles. Thromb Haemost 98:570\u2013578","journal-title":"Thromb Haemost"},{"key":"950_CR7","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1160\/TH05-04-0290","volume":"94","author":"C Geisen","year":"2005","unstructured":"Geisen C, Watzka M, Sittinger K, Steffens M, Daugela L, Seifried E, M\u00fcller CR, Wienker TF, Oldenburg J (2005) VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb Haemost 94:773\u2013779","journal-title":"Thromb Haemost"},{"key":"950_CR8","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1182\/blood-2008-03-144899","volume":"112","author":"D Wang","year":"2008","unstructured":"Wang D, Chen H, Momary KM, Cavallari LH, Johnson JA, Sad\u00e9e W (2008) Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood 112:1013\u20131021","journal-title":"Blood"},{"key":"950_CR9","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.1182\/blood-2009-12-255992","volume":"115","author":"NA Limdi","year":"2010","unstructured":"Limdi NA, Wadelius M, Cavallari L, Eriksson N, Crawford DC, Lee MT, Chen CH, Motsinger-Reif A, Sagreiya H, Liu N, Wu AH, Gage BF, Jorgensen A, Pirmohamed M, Shin JG, Suarez-Kurtz G, Kimmel SE, Johnson JA, Klein TE, Wagner MJ (2010) Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across three racial groups. Blood 115:3827\u20133834","journal-title":"Blood"},{"key":"950_CR10","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/j.1538-7836.2010.03792.x","volume":"8","author":"SA Lubitz","year":"2010","unstructured":"Lubitz SA, Scott SA, Rothlauf EB, Agarwal A, Peter I, Doheny D, Van Der Zee S, Jaremko M, Yoo C, Desnick RJ, Halperin JL (2010) Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population. J Thromb Haemost 8:1018\u20131026","journal-title":"J Thromb Haemost"},{"key":"950_CR11","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s00228-010-0809-2","volume":"66","author":"H Puehringer","year":"2010","unstructured":"Puehringer H, Loreth RM, Klose G, Schreyer B, Krugluger W, Schneider B, Oberkanins C (2010) VKORC1 -1639G>A and CYP2C9*3 are the major genetic predictors of phenprocoumon dose requirement. Eur J Clin Pharmacol 66:591\u2013598","journal-title":"Eur J Clin Pharmacol"},{"key":"950_CR12","doi-asserted-by":"publisher","first-page":"565","DOI":"10.2165\/00003088-200847090-00002","volume":"47","author":"S Stehle","year":"2008","unstructured":"Stehle S, Kirchheiner J, Lazar A, Fuhr U (2008) Pharmacogenetics of oral anticoagulants: a basis for dose individualization. Clin Pharmacokinet 47:565\u2013594","journal-title":"Clin Pharmacokinet"},{"key":"950_CR13","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1160\/TH08-04-0116","volume":"100","author":"M Beinema","year":"2008","unstructured":"Beinema M, Brouwers JR, Schalekamp T, Wilffert B (2008) Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon. Thromb Haemost 100:1052\u20131057","journal-title":"Thromb Haemost"},{"key":"950_CR14","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1046\/j.1365-2125.1998.00721.x","volume":"45","author":"JO Miners","year":"1998","unstructured":"Miners JO, Birkett DJ (1998) Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 45:525\u2013538","journal-title":"Br J Clin Pharmacol"},{"key":"950_CR15","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00228-004-0740-5","volume":"60","author":"M Ufer","year":"2004","unstructured":"Ufer M, Svensson JO, Krausz KW, Gelboin HV, Rane A, Tybring G (2004) Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro. Eur J Clin Pharmacol 60:173\u2013182","journal-title":"Eur J Clin Pharmacol"},{"key":"950_CR16","doi-asserted-by":"publisher","first-page":"4106","DOI":"10.1182\/blood-2007-11-122010","volume":"111","author":"MD Caldwell","year":"2008","unstructured":"Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, Gardina P, Hubbard J, Turpaz Y, Langaee TY, Eby C, King CR, Brower A, Schmelzer JR, Glurich I, Vidaillet HJ, Yale SH, Qi Zhang K, Berg RL, Burmester JK (2008) CYP4F2 genetic variant alters required warfarin dose. Blood 111:4106\u20134112","journal-title":"Blood"},{"key":"950_CR17","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2217\/14622416.10.2.261","volume":"10","author":"P Borgiani","year":"2009","unstructured":"Borgiani P, Ciccacci C, Forte V, Sirianni E, Novelli L, Bramanti P, Novelli G (2009) CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics 10:261\u2013266","journal-title":"Pharmacogenomics"},{"key":"950_CR18","doi-asserted-by":"publisher","first-page":"e1000433","DOI":"10.1371\/journal.pgen.1000433","volume":"5","author":"F Takeuchi","year":"2009","unstructured":"Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N, Whittaker P, Ranganath V, Kumanduri V, McLaren W, Holm L, Lindh J, Rane A, Wadelius M, Deloukas P (2009) A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 5:e1000433","journal-title":"PLoS Genet"},{"key":"950_CR19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1160\/TH05-06-0446","volume":"95","author":"M Vecsler","year":"2006","unstructured":"Vecsler M, Loebstein R, Almog S, Kurnik D, Goldman B, Halkin H, Gak E (2006) Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin. Thromb Haemost 95:205\u2013211","journal-title":"Thromb Haemost"},{"key":"950_CR20","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1111\/j.1538-7836.2007.02630.x","volume":"5","author":"R Gonz\u00e1lez-Conejero","year":"2007","unstructured":"Gonz\u00e1lez-Conejero R, Corral J, Rold\u00e1n V, Ferrer F, S\u00e1nchez-Serrano I, S\u00e1nchez-Blanco JJ, Mar\u00edn F, Vicente V (2007) The genetic interaction between VKORC1 c1173t and calumenin a29809g modulates the anticoagulant response of acenocoumarol. J Thromb Haemost 5:1701\u20131706","journal-title":"J Thromb Haemost"},{"key":"950_CR21","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1182\/blood-2003-09-3043","volume":"103","author":"E Shikata","year":"2004","unstructured":"Shikata E, Ieiri I, Ishiguro S, Aono H, Inoue K, Koide T, Ohgi S, Otsubo K (2004) Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood 103:2630\u20132635","journal-title":"Blood"},{"key":"950_CR22","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.thromres.2006.09.007","volume":"120","author":"R Kimura","year":"2007","unstructured":"Kimura R, Miyashita K, Kokubo Y, Akaiwa Y, Otsubo R, Nagatsuka K, Otsuki T, Okayama A, Minematsu K, Naritomi H, Honda S, Tomoike H, Miyata T (2007) Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb Res 120:181\u2013186","journal-title":"Thromb Res"},{"key":"950_CR23","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.clpt.2005.01.010","volume":"77","author":"R Loebstein","year":"2005","unstructured":"Loebstein R, Vecsler M, Kurnik D, Austerweil N, Gak E, Halkin H, Almog S (2005) Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9. Clin Pharmacol Ther 77:365\u2013372","journal-title":"Clin Pharmacol Ther"},{"key":"950_CR24","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/sj.tpj.6500313","volume":"5","author":"M Wadelius","year":"2005","unstructured":"Wadelius M, Chen LY, Downes K, Ghori J, Hunt S, Eriksson N, Wallerman O, Melhus H, Wadelius C, Bentley D, Deloukas P (2005) Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 5:262\u2013270","journal-title":"Pharmacogenomics J"},{"key":"950_CR25","first-page":"1510","volume":"89","author":"RL D\u2019Ambrosio","year":"2004","unstructured":"D\u2019Ambrosio RL, D\u2019Andrea G, Cappucci F, Chetta M, Di Perna P, Brancaccio V, Grandone E, Margaglione M (2004) Polymorphisms in factor II and factor VII genes modulate oral anticoagulation with warfarin. Haematologica 89:1510\u20131516","journal-title":"Haematologica"},{"key":"950_CR26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00439-006-0260-8","volume":"121","author":"M Wadelius","year":"2007","unstructured":"Wadelius M, Chen LY, Eriksson N, Bumpstead S, Ghori J, Wadelius C, Bentley D, McGinnis R, Deloukas P (2007) Association of warfarin dose with genes involved in its action and metabolism. Hum Genet 121:23\u201334","journal-title":"Hum Genet"},{"key":"950_CR27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/clpt.2009.178","volume":"87","author":"E Pautas","year":"2010","unstructured":"Pautas E, Moreau C, Gouin-Thibault I, Golmard JL, Mah\u00e9 I, Legendre C, Taillandier-H\u00e9riche E, Durand-Gasselin B, Houllier AM, Verrier P, Beaune P, Loriot MA, Siguret V (2010) Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. Clin Pharmacol Ther 87:57\u201364","journal-title":"Clin Pharmacol Ther"},{"key":"950_CR28","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.2217\/pgs.09.106","volume":"10","author":"MT Lee","year":"2009","unstructured":"Lee MT, Chen CH, Chou CH, Lu LS, Chuang HP, Chen YT, Saleem AN, Wen MS, Chen JJ, Wu JY, Chen YT (2009) Genetic determinants of warfarin dosing in the Han-Chinese population. Pharmacogenomics 10:1905\u20131913","journal-title":"Pharmacogenomics"},{"key":"950_CR29","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00228-009-0768-7","volume":"66","author":"J Cadamuro","year":"2010","unstructured":"Cadamuro J, Dieplinger B, Felder T, Kedenko I, Mueller T, Haltmayer M, Patsch W, Oberkofler H (2010) Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements. Eur J Clin Pharmacol 66:253\u2013260","journal-title":"Eur J Clin Pharmacol"},{"key":"950_CR30","first-page":"447","volume":"58","author":"M Schulz","year":"2003","unstructured":"Schulz M, Schmoldt A (2003) Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics. Pharmazie 58:447\u2013474","journal-title":"Pharmazie"},{"key":"950_CR31","author":"B Luxembourg","year":"2010","unstructured":"Luxembourg B, Schneider K, Sittinger K, Toennes SW, Seifried E, Lindhoff-Last E, Oldenburg J, Geisen C. Impact of pharmacokinetic (CYP2C9) and pharmacodynamic (VKORC1, F7, GGCX, CALU, EPHX1) gene variants on the initiation and maintenance phases of phenprocoumon therapy. Thromb Haemost. doi:10.1160\/TH10-03-0194.","journal-title":"Thromb Haemost"},{"key":"950_CR32","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1182\/blood-2005-01-0341","volume":"106","author":"L Bodin","year":"2005","unstructured":"Bodin L, Verstuyft C, Tregouet DA, Robert A, Dubert L, Funck-Brentano C, Jaillon P, Beaune P, Laurent-Puig P, Becquemont L, Loriot MA (2005) Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 106:135\u2013140","journal-title":"Blood"},{"key":"950_CR33","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.2217\/14622416.9.11.1631","volume":"9","author":"CN Markatos","year":"2008","unstructured":"Markatos CN, Grouzi E, Politou M, Gialeraki A, Merkouri E, Panagou I, Spiliotopoulou I, Travlou A (2008) VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients. Pharmacogenomics 9:1631\u20131638","journal-title":"Pharmacogenomics"},{"key":"950_CR34","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s00228-003-0580-8","volume":"59","author":"E Hummers-Pradier","year":"2003","unstructured":"Hummers-Pradier E, Hess S, Adham IM, Papke T, Pieske B, Kochen MM (2003) Determination of bleeding risk using genetic markers in patients taking phenprocoumon. Eur J Clin Pharmacol 59:213\u2013219","journal-title":"Eur J Clin Pharmacol"},{"key":"950_CR35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/00008571-200401000-00003","volume":"14","author":"LE Visser","year":"2004","unstructured":"Visser LE, van Vliet M, van Schaik RH, Kasbergen AA, De Smet PA, Vulto AG, Hofman A, van Duijn CM, Stricker BH (2004) The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Pharmacogenetics 14:27\u201333","journal-title":"Pharmacogenetics"},{"key":"950_CR36","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.clpt.2004.08.006","volume":"76","author":"T Schalekamp","year":"2004","unstructured":"Schalekamp T, Oosterhof M, van Meegen E, van Der Meer FJ, Conemans J, Hermans M, Meijerman I, de Boer A (2004) Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status. Clin Pharmacol Ther 76:409\u2013417","journal-title":"Clin Pharmacol Ther"},{"key":"950_CR37","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1365-2125.1977.tb00786.x","volume":"4","author":"S Husted","year":"1977","unstructured":"Husted S, Andreasen F (1977) The influence of age on the response to anticoagulants. Br J Clin Pharmacol 4:559\u2013565","journal-title":"Br J Clin Pharmacol"},{"key":"950_CR38","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMra032424","volume":"352","author":"GR Wilkinson","year":"2005","unstructured":"Wilkinson GR (2005) Drug metabolism and variability among patients in drug response. N Engl J Med 352:2211\u20132221","journal-title":"N Engl J Med"},{"key":"950_CR39","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1093\/hmg\/ddp309","volume":"18","author":"M Teichert","year":"2009","unstructured":"Teichert M, Eijgelsheim M, Rivadeneira F, Uitterlinden AG, van Schaik RH, Hofman A, De Smet PA, van Gelder T, Visser LE, Stricker BH (2009) A genome-wide association study of acenocoumarol maintenance dosage. Hum Mol Genet 18:3758\u20133768","journal-title":"Hum Mol Genet"},{"key":"950_CR40","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1182\/blood-2008-01-134247","volume":"112","author":"GM Cooper","year":"2008","unstructured":"Cooper GM, Johnson JA, Langaee TY, Feng H, Stanaway IB, Schwarz UI, Ritchie MD, Stein CM, Roden DM, Smith JD, Veenstra DL, Rettie AE, Rieder MJ (2008) A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 112:1022\u20131027","journal-title":"Blood"},{"key":"950_CR41","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1515\/CCLM.2007.190","volume":"45","author":"ML Hannuksela","year":"2007","unstructured":"Hannuksela ML, Liisanantti MK, Nissinen AE, Savolainen MJ (2007) Biochemical markers of alcoholism. Clin Chem Lab Med 45:953\u2013961","journal-title":"Clin Chem Lab Med"},{"key":"950_CR42","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1369-1600.2006.00040.x","volume":"12","author":"S Hartmann","year":"2007","unstructured":"Hartmann S, Aradottir S, Graf M, Wiesbeck G, Lesch O, Ramskogler K, Wolfersdorf M, Alling C, Wurst FM (2007) Phosphatidylethanol as a sensitive and specific biomarker: comparison with gamma-glutamyl transpeptidase, mean corpuscular volume and carbohydrate-deficient transferrin. Addict Biol 12:81\u201384","journal-title":"Addict Biol"},{"key":"950_CR43","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1007\/s11606-009-0949-1","volume":"24","author":"KN Kangelaris","year":"2009","unstructured":"Kangelaris KN, Bent S, Nussbaum RL, Garcia DA, Tice JA (2009) Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin. J Gen Intern Med 24:656\u2013664","journal-title":"J Gen Intern Med"},{"key":"950_CR44","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.1538-7836.2009.03677.x","volume":"8","author":"NS Ferder","year":"2010","unstructured":"Ferder NS, Eby CS, Deych E, Harris JK, Ridker PM, Milligan PE, Goldhaber SZ, King CR, Giri T, McLeod HL, Glynn RJ, Gage BF (2010) Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. J Thromb Haemost 8:95\u2013100","journal-title":"J Thromb Haemost"},{"key":"950_CR45","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1182\/blood-2008-09-176859","volume":"113","author":"C Li","year":"2009","unstructured":"Li C, Schwarz UI, Ritchie MD, Roden DM, Stein CM, Kurnik D (2009) Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Blood 113:3925\u20133930","journal-title":"Blood"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-010-0950-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-010-0950-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-010-0950-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-010-0950-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,4]],"date-time":"2023-06-04T08:36:50Z","timestamp":1685867810000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-010-0950-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,26]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["950"],"URL":"https:\/\/doi.org\/10.1007\/s00228-010-0950-y","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,26]]},"assertion":[{"value":"13 August 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}